Anne Chiang, MD, PhD, discusses the management of immune-related adverse effects in lung cancer.
Anne Chiang, MD, PhD, associate professor, Yale School of Medicine, chief network officer and deputy chief medical officer, Smilow Cancer Network, discusses the management of immune-related adverse effects (irAEs) in lung cancer.
It is critical to conduct a thorough toxicity evaluation in patients with lung cancer who are receiving immunotherapy, Chiang says. This is commonly done in the clinical trial setting, and it should also be a part of everyday practice, says Chiang.
Common irAEs include diarrhea and skin toxicities. To quantify irAEs, it may be beneficial for patients to keep a diary that patients can refer to in follow-up appointments, Chiang notes.
Notably, it’s important to keep irAEs in mind when a patient presents with an ailment such as low blood pressure. In some cases, more serious irAEs such as adrenal insufficiency, hypophysitis, or encephalitis can be mistaken for dehydration, Chiang concludes.